About Putative RNA-binding protein Luc7-like 2
Putative RNA-binding protein Luc7-like 2 (LUC7L2) is a protein
from Homo sapiens identified by UniProt accession
Q9Y383, 392 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | Putative RNA-binding protein Luc7-like 2 |
| UniProt accession | Q9Y383 |
| Gene | LUC7L2 |
| Organism | Homo sapiens |
| Length | 392 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (28)
Diseases linked to this target (Open Targets).
- Usher syndrome · score 0.27
- neurodegenerative disease · score 0.18
- reticulocyte count · score 0.17
- reticulocyte measurement · score 0.11
- BMI-adjusted waist circumference · score 0.10
- glioblastoma multiforme · score 0.03
- myeloid neoplasm · score 0.01
- Abnormal sperm morphology · score 0.01
- myelodysplastic syndrome · score 0.01
- head and neck squamous cell carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y383-F1 | alphafold | PREDICTED | 66.33 | — |
Amino-acid sequence (392 residues)
MSAQAQMRAM LDQLMGTSRD GDTTRQRIKF SDDRVCKSHL LNCCPHDVLS GTRMDLGECL KVHDLALRAD YEIASKEQDF FFELDAMDHL QSFIADCDRR TEVAKKRLAE TQEEISAEVA AKAERVHELN EEIGKLLAKV EQLGAEGNVE ESQKVMDEVE KARAKKREAE EVYRNSMPAS SFQQQKLRVC EVCSAYLGLH DNDRRLADHF GGKLHLGFIE IREKLEELKR VVAEKQEKRN QERLKRREER EREEREKLRR SRSHSKNPKR SRSREHRRHR SRSMSRERKR RTRSKSREKR HRHRSRSSSR SRSRSHQRSR HSSRDRSRER SKRRSSKERF RDQDLASCDR DRSSRDRSPR DRDRKDKKRS YESANGRSED RRSSEEREAG EI
Explore Putative RNA-binding protein Luc7-like 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets